Prosecution Insights
Last updated: November 12, 2026
Application No. 18/236,218

GENETICALLY MODIFIED NON-HUMAN ANIMALS AND METHODS OF USE THEREOF

Final Rejection §103§DOUBLEPATENT
Filed
Aug 21, 2023
Priority
Nov 05, 2012 — provisional 61/722,437 +3 more
Examiner
MONTANARI, DAVID A
Art Unit
1632
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Institute For Research In Biomedicine (Irb)
OA Round
2 (Final)
65%
Grant Probability
Moderate
3-4
OA Rounds
99%
With Interview

Examiner Intelligence

Grants 65% of resolved cases
65%
Career Allowance Rate
503 granted / 777 resolved
+4.7% vs TC avg
Strong +49% interview lift
Without
With
+49.2%
Interview Lift
resolved cases with interview
Typical timeline
Avg Prosecution
55 currently pending
Career history
841
Total Applications
across all art units

Office Action

§103 §DOUBLEPATENT
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application is being examined under the pre-AIA first to invent provisions. Applicants arguments filed on 2/5/20206 have been entered. Claims 25-42 are examined in the instant application. Double Patenting The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the “right to exclude” granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., In re Berg, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); In re Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Ornum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969). A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on nonstatutory double patenting provided the reference application or patent either is shown to be commonly owned with the examined application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement. See MPEP § 717.02 for applications subject to examination under the first inventor to file provisions of the AIA as explained in MPEP § 2159. See MPEP § 2146 et seq. for applications not subject to examination under the first inventor to file provisions of the AIA . A terminal disclaimer must be signed in compliance with 37 CFR 1.321(b). The filing of a terminal disclaimer by itself is not a complete reply to a nonstatutory double patenting (NSDP) rejection. A complete reply requires that the terminal disclaimer be accompanied by a reply requesting reconsideration of the prior Office action. Even where the NSDP rejection is provisional the reply must be complete. See MPEP § 804, subsection I.B.1. For a reply to a non-final Office action, see 37 CFR 1.111(a). For a reply to final Office action, see 37 CFR 1.113(c). A request for reconsideration while not provided for in 37 CFR 1.113(c) may be filed after final for consideration. See MPEP §§ 706.07(e) and 714.13. The USPTO Internet website contains terminal disclaimer forms which may be used. Please visit www.uspto.gov/patent/patents-forms. The actual filing date of the application in which the form is filed determines what form (e.g., PTO/SB/25, PTO/SB/26, PTO/AIA /25, or PTO/AIA /26) should be used. A web-based eTerminal Disclaimer may be filled out completely online using web-screens. An eTerminal Disclaimer that meets all requirements is auto-processed and approved immediately upon submission. For more information about eTerminal Disclaimers, refer to www.uspto.gov/patents/apply/applying-online/eterminal-disclaimer. Claims 25-42 remain rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-11 of U.S. Patent No. 11,778,995 in view of Hansen et al. (2004, European J. Cancer, Vol. 40, pgs. 858-880) since the instant invention generates an identical mouse to be used by the method of screening in ‘995 for reasons of record in the Non-Final Office Action mailed on 11/5/2025 (and repeated below). Further, Hansen et al. teach that at the time of filing it was obvious to use transgenic mouse models for screening candidate drugs for the treatment of cancer. Further regarding the instant dependent claims they would be obvious over the dependent claims of ‘995 since the ES cells and embryo would be used in the creation of the transgenic mouse that would be used in the method of screening of ‘995. The instant application was filed as a CON and the court has found that safe harbor does not apply when the continuing application is filed as CON. The court found that safe harbor from an ODP rejection only applies when a continuing application is filed as a DIV. See AMGEN INC., v. F. HOFFMANN-LA ROCHE LTD. 580 F.3d l340; 2009 U.S. App, LEXIS 20409; 92 U.S.P.Q.2D (BNA) 1289. Response to Arguments Applicants’ Arguments Applicants argue in amendment that the instant claims are patently distinct from the claims of ‘995. Examiner’s Response While Applicants argument has been fully considered it is not found persuasive the claims remain rejection as ODP for the reasons of record and above. Claims 25-42 remain rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-10 of U.S. Patent No. 10,785,968 in view of Hansen et al. (2004, European J. Cancer, Vol. 40, pgs. 858-880) since the instant invention generates an identical mouse to be used by the method of screening in ‘968 for reasons of record in the Non-Final Office Action mailed on 11/5/2025 (and repeated below). Further, Hansen et al. teach that at the time of filing it was obvious to use transgenic mouse models for modeling human B cell development and function (see Table 1). Further regarding the instant dependent claims they would be obvious over the dependent claims of ‘968 since the ES cells and embryo would be used in the creation of the transgenic mouse that would be used in the method of generating a mouse model of human B cell development of ‘968. The instant application was filed as a CON and the court has found that safe harbor does not apply when the continuing application is filed as CON. The court found that safe harbor from an ODP rejection only applies when a continuing application is filed as a DIV. See AMGEN INC., v. F. HOFFMANN-LA ROCHE LTD. 580 F.3d l340; 2009 U.S. App, LEXIS 20409; 92 U.S.P.Q.2D (BNA) 1289. Response to Arguments Applicants’ Arguments Applicants argue in amendment that the instant claims are patently distinct from the claims of ‘968. Examiner’s Response While Applicants argument has been fully considered it is not found persuasive the claims remain rejection as ODP for the reasons of record and above. Claims 25-42 remain rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-6 of U.S. Patent No. 9,901,082 in view of Hansen et al. (2004, European J. Cancer, Vol. 40, pgs. 858-880) since the instant invention generates an identical mouse that will comprise engrafted hematopoietic cells in ‘082 for reasons of record in the Non-Final Office Action mailed on 11/5/2025 (and repeated below). Further, Hansen et al. teach that at the time of filing it was obvious to use engrafted cells in transgenic mouse models for modeling human B cell development and function (see Table 1). Further regarding the instant dependent claims they would be obvious over the dependent claims of ‘082 since the ES cells and embryo would be used in the creation of the transgenic mouse claimed in ‘082. The instant application was filed as a CON and the court has found that safe harbor does not apply when the continuing application is filed as CON. The court found that safe harbor from an ODP rejection only applies when a continuing application is filed as a DIV. See AMGEN INC., v. F. HOFFMANN-LA ROCHE LTD. 580 F.3d l340; 2009 U.S. App, LEXIS 20409; 92 U.S.P.Q.2D (BNA) 1289. Response to Arguments Applicants’ Arguments Applicants argue in amendment that the instant claims are patently distinct from the claims of ‘082. Examiner’s Response While Applicants argument has been fully considered it is not found persuasive the claims remain rejection as ODP for the reasons of record and above. Claim Rejections - 35 USC § 103 The following is a quotation of pre-AIA 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action: (a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made. Claims 25, 28, 31, 34, 37 and 40 remain rejected under pre-AIA 35 U.S.C. 103(a) as being obvious over Strowig et al. (2011, PNAS, Vol. 108, pgs. 13218-13223) in view of Wang et al. (U.S. Patent No. 8,878,001 B2, filed 10/29/2012) and King et al. (2008, Clinical Immunology, Vol. 126, pgs. 303-314) for reasons of record in the Non-Final Office Action mailed on 11/5/2025 (and repeated below). The applied reference has a common inventor with the instant application. Based upon the earlier effective U.S. filing date of the reference, it constitutes prior art under pre-AIA 35 U.S.C. 102(e). This rejection under pre-AIA 35 U.S.C. 103(a) might be overcome by: (1) a showing under 37 CFR 1.132 that any invention disclosed but not claimed in the reference was derived from the inventor of this application and is thus not an invention “by another”; (2) a showing of a date of invention for the claimed subject matter of the application which corresponds to subject matter disclosed but not claimed in the reference, prior to the effective U.S. filing date of the reference under 37 CFR 1.131(a); or (3) an oath or declaration under 37 CFR 1.131(c) stating that the application and reference are currently owned by the same party and that the inventor (i.e., the inventive entity) named in the application is the prior inventor under pre-AIA 35 U.S.C. 104 as in effect on March 15, 2013, together with a terminal disclaimer in accordance with 37 CFR 1.321(c). This rejection might also be overcome by showing that the reference is disqualified under pre-AIA 35 U.S.C. 103(c) as prior art in a rejection under pre-AIA 35 U.S.C. 103(a). See MPEP § 706.02(l)(1) and § 706.02(l)(2). Regarding claims 25, 28, 37 and 40, Strowig et al. teach a method of generating a Rag2 -/- γc -/- knockout mouse, via an ES cell, whose genome comprises a nucleic acid encoding human SIRPa operably linked to the human SIRPa promoter, wherein the said nucleic acid is randomly integrated (see Abstract and pg. 13218 col. 2 last parag. bridge pg. 13219 col. 1 parag. 1). Regarding claims GM-CSF, IL-3 and TPO, Strowig teaches that “Recently, several approaches have been used to improve human cell engraftment and the unbalanced lineage differentiation in CD34+ cell engrafted mice. These include transient approaches such as hydrodynamic injection of plasmid DNA (34), injections of cytokines, and infections of mice or CD34+ cells with lentiviruses (35–37). Alternatively, transgenic expression of human MHC molecules has been demonstrated to improve the development of antigen-specific immune responses in vivo (38–40). Nonetheless, overexpression of cytokines might also have detrimental side effects due to the unphysiological expression such as in mice transgenic for SCF, GM-CSF, and IL-3 (41). An alternative approach to provide human growth factors in vivo is to genetically engineer mice and replace the mouse genes with their human counterparts resulting in their expression in the appropriate niche at physiological levels. Indeed, faithful replacement of mouse GM-CSF and IL-3 as well as thrombopoietin (TPO) by our group has resulted in improved development of human macrophages in the lung and HSC and HPC maintenance in the bone marrow, respectively (23, 24). Notably, in human TPO knockin mice, despite a highly increased engraftment level of stem and progenitor cells in the bone marrow, no changes were observed in the periphery, demonstrating the existence of limiting factors in the periphery such as destruction by phagocytes. With the hSIRPa-DKO mice, we have generated a strain that combines superior engraftment level and the possibility of long-term genetic manipulations to further enhance the murine host” (pg. 13222 col. 1 parag. 2 bridge col. 2 parag. 1). Strowig et al. does not teach: an immunodeficient human SIRPa expressing mouse that also expresses human IL-6; a Rag2 -/- IL-2rg -/- knockout mouse (i) Wang et al. teach: “Genetically modified mice are provided that express a human IL-6 and/or a humanized IL-6 receptor from endogenous mouse loci, wherein the endogenous mouse IL-6 gene and/or the endogenous mouse IL-6 receptor gene have been replaced with a human IL-6 gene and/or a human sequence comprising a sequence that encodes an ectodomain of a human IL-6 receptor. The genetically modified mice express the human IL-6 and/ or humanized IL-6 receptor from humanized endogenous loci that are under control of mouse promoters and/or mouse regulatory elements. The replacement(s) at the endogenous mouse loci provide non-human animals that express human IL-6 and a humanized IL-6 receptor in a manner that does not result in the panoply of substantial pathologies observed in IL-6 transgenic mice known in the art." (col. 10, lines 58-67 bridge col. 11 lines 1-5). Wang continues to teach that “the inventors demonstrate that a replacement with human sequence at an endogenous locus under control of endogenous regulatory elements provides a physiologically appropriate expression pattern and level that results in a useful humanized animal whose physiology with respect to the replaced gene are meaningful and appropriate and context of the humanized animal's physiology.” (col. 11 lines 37-43). Wang continues to teach that “IL-6 in humans mediates the acute phase response, hematopoiesis, B cell differentiation, T cell activation, growth and/ or differentiation and/ or activation of a variety of cell types (e.g., hepatocytes, fibroblasts, endothelial cells, neurons, pituitary cells, lymphomas, myelomas, breast carcinomas, NK cells, macrophages, osteoclasts, etc.)” (col. 9 lines 8-13). Regarding an embryo in claims 31 and 34, Wang teaches that they can generate a mouse embryo which comprises the human IL-6 gene (col. 6 lines 1-19). Regarding knocking out IL-2rg -/-, King et al. teach that “Recent breakthroughs in the generation of improved recipients for human hematopoietic cell engraftment have been based on immunodeficient mice bearing a targeted mutation in the IL-2 receptor common gamma chain (Il2rγ) locus” (pg. 304, col. 1 parag. 3 lines 1-4). King continues to teach a NOD-scid Il2rγnull mouse and that “Immunodeficient NOD-scid mice bearing a targeted mutation in the IL2 receptor common gamma chain (Il2rγnull) readily engraft with human stem cells” (Abstract lines 1-2). Thus the ordinary artisan would have it prima facie obvious at the time of filing to modify the teachings of Strowig regarding a Rag2 -/- γc -/- knockout mouse expressing human SIRPa with the teachings of Wang regarding replacing the endogenous mouse IL-6 gene with a human IL-6 gene and with the teachings of King regarding the benefits of knocking out the IL-2rg gene in a mouse to arrive at the claimed invention. One of ordinary skill in the art would have been motivated to make such a combination since Strowig teaches that to improve human cell engraftment and the unbalanced lineage differentiation in CD34+ cell engrafted mice, human growth factors can be provided in vivo in genetically engineered mice by replacing the mouse genes with their human counterparts which improves development of human macrophages in the lung and HSC and HPC maintenance in the bone marrow. Thus incorporating human genes such as, IL-3, IL-6 and TPO, for example, would have been an obvious and advantageous modification of the mouse of Strowig. Further motivation is provided by King to substitute a knockout of the IL-2rg gene for γc since King teaches that knocking out IL-2rg results is an improvement in immunodeficient mice for engrafting human cells. One of skill in the art would have had a reasonable expectation of making the claimed genetically-modified mouse as the technology for homologous recombination to make genetically-modified mice was well known at the time of filing. Thus the cited art provides the requisite teaching and motivations to make and use the inventions as claimed. Response to Arguments Applicants’ Arguments Applicants argue in amendment that Strowig recites that "faithful replacement of mouse GM-CSF and IL-3 as well as thrombopoietin (TPO) by our group has resulted in improved development of human macrophages in the lung and HSC and HPC maintenance in the bone marrow, respectively " Strowig, pg. 13222. However, Strowig provides no teaching, suggestion, or guidance to support the Office's allegation that incorporating human IL-6 would have been an obvious and advantageous modification of the mice described therein. While Wang relates to mice that comprise a replacement of endogenous mouse IL-6 and/or IL-6 receptor, Wang does not teach or suggest that replacement of endogenous mouse IL-6 with human IL-6 would yield a mouse that can support growth of engrafted human hematopoietic cells. Accordingly, the proposed combination of Strowig and Wang does not provide one of ordinary skill in the art any teaching, suggestion, or guidance to modify Strowig's transgenic SIRPa mouse to express a human IL-6 from the mouse IL-6 locus in order to arrive at the instant claims. Further, one of ordinary skill in the art would have had no reasonable expectation of success with respect to the proposed modification in the context of the teachings of Strowig and Wang, at least because Strowig is silent with respect to IL-6 and Wang is silent with respect to features that make a transgenic mouse receptive to engraftment of human hematopoietic cells. In view of the above, Applicants respectfully submit that the Office has failed to establish a prima facie case of obviousness with respect to the claims as currently amended. Even if a prima facie case of obviousness was established based on the proposed combinations of references (which Applicants do not concede), the application as filed provides evidence of unexpected results with respect to the presently claimed ES cells which may be used to generate the genetically modified mice described in the instant working examples, which outweigh any such prima facie case. For example, the application as filed provides experimental data showing that, when engrafted with human hematopoietic cells, mice comprising in their genome a nucleic acid encoding human IL-6 operably linked to the mouse IL-6 promoter at the mouse IL-6 locus produce higher levels of total human IgG as compared to an immunodeficient mouse engrafted with human hematopoietic cells and lacking such a nucleic acid. See, for example, Fig. 15 of the application as filed. Thus, the application as filed provides evidence that human B cells differentiate into human lgG secreting plasma cells which secrete higher levels of total human IgG in a genetically modified mouse as compared to a mouse engrafted with human hematopoietic cells and lacking a nucleic acid encoding human IL-6 operably linked to the mouse IL-6 promoter at the mouse IL-6 locus. Such a result would not have been expected from the disclosures of the cited references. Furthermore, the presently claimed ES cells are particularly suited for generating mice having genetically modified genomes that both support the engraftment of such human hematopoietic cells (see Example 1) as well as the development of human plasma cells that secrete higher levels of IgG from those engrafted human hematopoietic cells (see Example 2). In view of the above, Applicants respectfully submit that the Office has failed to establish a prima facie case of obviousness with respect to the claims as currently amended. Reconsideration and withdrawal of the rejection are respectfully requested. The deficiencies in the proposed combination of Strowig and Wang are discussed above. As the Office relies on King solely for disclosing a NOD-scid mouse, King fails to cure the deficiencies of Strowig and Wang. Examiner’s Response While Applicants arguments have been fully considered they are not found persuasive. Specifically, while Applicants arguments regarding unexpected results have been considered they are not found persuasive in view of MPEP 716.02(a), since none of the unexpected results that Applicants argue are claim limitations. Further it is maintained that the ordinary artisan would have found it obvious to combine the teachings of Wang regarding IL-6 with Strowig, with Wang specifically teaching (as set forth above) that their model expressing human IL-6 permits “physiologically appropriate expression pattern and level that results in a useful humanized animal whose physiology with respect to the replaced gene are meaningful and appropriate and context of the humanized animal's physiology”. Thus for the reasons above and of record the rejection is maintained. Claims 26, 27, 29, 30, 32, 33, 35, 36, 38, 39, 41 and 42 remain rejected under pre-AIA 35 U.S.C. 103(a) as being unpatentable over Strowig et al. (2011, PNAS, Vol. 108, pgs. 13218-13223) in view of Wang et al. (U.S. Patent No. 8,878,001 B2, filed 10/29/2012) and King et al. (2008, Clinical Immunology, Vol. 126, pgs. 303-314) as applied to claims 25, 28, 31, 34, 37 and 40 above, and further in view of Bernier et al. (2001, Exp. Toxic Pathol., Vol. 53, pgs. 165-173) and NCBI nucleotide sequence encoding human M-CSF, 2005) for reasons of record in the Non-Final Office Action mailed on 11/5/2025 (and repeated below). Strowig, Wang and King are relied upon above in teaching a method of a making a genetically modified mouse. Strowig, Wang and King do not teach: Expressing M-CSF. Regarding expressing M-CSF, Bernier et al. teach a transgenic mouse overexpressing mouse M-CSF (pg. 166 col. 2 parag. 2 and Fig. 1) and teaches (citations omitted) “Macrophage colony stimulating factor (M-CSF) stimulates the proliferation, activation and differentiation of macrophage precursor cells and promotes the activation and proliferation of mature mouse macrophages. M-CSF has been reported to influence various functions of mature mononuclear phagocytes, and is also a potent chemoattractant” (pg. 165 col. 1 last two lines bridge col. 2 lines 1-7). While Bernier used the murine M-CSF sequence to generate their transgenic mouse, at the time of filing the human nucleotide sequence encoding M-CSF was known as set forth in the attached sequence report from NCBI. Thus the ordinary artisan would have it prima facie obvious at the time of filing to modify the teachings of Strowig, Wang and King regarding a Rag2 -/- γc -/- knockout mouse expressing human SIRPa with the teachings of Bernier regarding overexpressing M-CSF in a mouse to arrive at the claimed invention. One of ordinary skill in the art would have been motivated to make such a combination since Bernier teaches that M-CSF expression is involved in the immune system through macrophage development. One of skill in the art would have had a reasonable expectation that human M-CSF could be expressed in the transgenic mouse of Strowig, Wang and King since Bernier teaches successful expression of M-CSF in a mouse and that the human nucleotide sequence encoding M-CSF was known at the time of filing. Thus the cited art provides the requisite teaching and motivations to make and use the inventions as claimed. Response to Arguments Applicants’ Arguments Applicants argue in amendment that the rejection of claims 25-42 under 35 U.S.C. $103(a) has been adequately addressed in view of the remarks set forth above. Examiner’s Response While Applicants argument has been fully considered it is not found persuasive the claims remain rejection as being obvious in view of the rejection above. Conclusion No claims are allowed. THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to DAVID A MONTANARI whose telephone number is (571)272-3108. The examiner can normally be reached M-Tr 8-6. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Peter Paras can be reached at 571-272-4517. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. DAVID A. MONTANARI Examiner Art Unit 1632 /ANOOP K SINGH/Primary Examiner, Art Unit 1632
Read full office action

Prosecution Timeline

Aug 21, 2023
Application Filed
Nov 05, 2025
Non-Final Rejection mailed — §103, §DOUBLEPATENT
Feb 05, 2026
Response Filed
Sep 23, 2026
Final Rejection mailed — §103, §DOUBLEPATENT
Nov 10, 2026
Interview Requested

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12747453
GENE-THERAPY VECTORS FOR TREATING CARDIOMYOPATHY
3y 1m to grant Granted Sep 29, 2026
Patent 12742181
GENE-THERAPY VECTORS FOR TREATING CARDIOMYOPATHY
3y 8m to grant Granted Sep 22, 2026
Patent 12703854
IN VITRO METHOD OF DIFFERENTIATING A HUMAN PLURIPOTENT STEM CELL POPULATION INTO A CARDIOMYOCYTE CELL POPULATION
4y 11m to grant Granted Aug 11, 2026
Patent 12698310
COMPOSITIONS AND METHODS FOR INSECT CONTROL
5y 0m to grant Granted Aug 04, 2026
Patent 12692481
BACULOVIRUS EXPRESSION SYSTEM
6y 1m to grant Granted Jul 28, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4
Expected OA Rounds
65%
Grant Probability
99%
With Interview (+49.2%)
Moderate
PTA Risk
Based on 777 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month